Analysis of Patient Preferences in Lung Cancer – Estimating Acceptable Tradeoffs Between Treatment Benefit and Side Effects

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?

(2019) Masayuki Takeda et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review

(2019) Vikas Soekhai et al.   DRUG DISCOVERY TODAY

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial

(2019) Giorgio V Scagliotti et al.   Lancet Respiratory Medicine

The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer

(2019) Michael J. Raphael et al.   JAMA Oncology

Project Transform: engaging patient advocates to share their perspectives on improving research, treatment and policy

(2018) John F. P. Bridges et al.   CURRENT MEDICAL RESEARCH AND OPINION

Conducting a Discrete-Choice Experiment Study Following Recommendations for Good Research Practices: An Application for Eliciting Patient Preferences for Diabetes Treatments

(2018) Ellen M. Janssen et al.   VALUE IN HEALTH

Effect of Level Overlap and Color Coding on Attribute Non-Attendance in Discrete Choice Experiments

(2018) Marcel F. Jonker et al.   VALUE IN HEALTH

Research as an event: a novel approach to promote patient-focused drug development

(2018) Jui-Hua Tsai et al.   Patient Preference and Adherence

A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group

(2018) Tao Jiang et al.   Journal of Thoracic Disease

Discrete Choice Experiments in Health Economics: Past, Present and Future

(2018) Vikas Soekhai et al.   PHARMACOECONOMICS

Using Latent Class Analysis to Model Preference Heterogeneity in Health: A Systematic Review

(2017) Mo Zhou et al.   PHARMACOECONOMICS

Education and patient preferences for treating type 2 diabetes: a stratified discrete-choice experiment

(2017) Ellen M Janssen et al.   Patient Preference and Adherence

Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force

(2016) A. Brett Hauber et al.   VALUE IN HEALTH

Patient Preferences in Regulatory Benefit-Risk Assessments: A US Perspective

(2016) F. Reed Johnson et al.   VALUE IN HEALTH

Preferences of lung cancer patients for treatment and decision-making: a systematic literature review

(2015) K. Schmidt et al.   EUROPEAN JOURNAL OF CANCER CARE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

(2014) E. Basch et al.   JNCI-Journal of the National Cancer Institute

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Discrete Choice Experiments in Health Economics: A Review of the Literature

(2014) Michael D. Clark et al.   PHARMACOECONOMICS

Constructing Experimental Designs for Discrete-Choice Experiments: Report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force

(2013) F. Reed Johnson et al.   VALUE IN HEALTH

Patients’ preferences for treatment outcomes for advanced non-small cell lung cancer: A conjoint analysis

(2012) John F.P. Bridges et al.   LUNG CANCER

Can scale and coefficient heterogeneity be separated in random coefficients models?

(2012) Stephane Hess et al.   TRANSPORTATION

Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force

(2011) John F.P. Bridges et al.   VALUE IN HEALTH

Discrete choice experiments in health economics: a review of the literature

(2010) Esther W. de Bekker-Grob et al.   HEALTH ECONOMICS

Estimating importance weights for the IWQOL-Lite using conjoint analysis

(2010) A. Brett Hauber et al.   QUALITY OF LIFE RESEARCH

Utility in Willingness to Pay Space: A Tool to Address Confounding Random Scale Effects in Destination Choice to the Alps

(2008) Riccardo Scarpa et al.   AMERICAN JOURNAL OF AGRICULTURAL ECONOMICS

Using Conjoint Analysis to Estimate Healthy-Year Equivalents for Acute Conditions: An Application to Vasomotor Symptoms

(2008) F. Reed Johnson et al.   VALUE IN HEALTH